Published Date: 16 Feb 2023
Many physicians have encountered one or more serious or potentially dangerous patients over the years, and according to Medscape research, patient trust has declined.
Read Full NewsCould timing prostate cancer radiotherapy according to patients’ circadian rhythm genes reduce the risk for late side effects?
Progression-free survival with the multitarget PAM inhibitor approaches 10 months after anti-CDK4/6 and aromatase inhibitor failure.
Researchers retrospectively analyzed outcomes for 50 patients with biopsy-proven monoclonal gammopathy of renal significance for a median follow-up of 6.15 years.
In a small single-center study, 1-year survival is 100% among carefully selected patients who undergo bilateral lung transplantation for stage IV disease confined to the lungs.
1.
Why palliative care goes hand in hand with treatment for people with cancer: Q&A
2.
Cancer tumor anatomy influences the benefits of chemotherapy for patients with early-stage breast cancer.
3.
Fixed-Duration Oral Doublet for Fit CLL Wins in Frontline Setting
4.
Inner Thoughts of Leonard Bernstein, the "Maestro".
5.
PSA Screening Overdiagnosis Rises Sharply With Age
1.
Generative AI for Adaptive Oncology Trial Design
2.
Transformative Frameworks in Oncology for Better Care
3.
Red Blood Cell Microparticles: Tiny Warriors Against Bleeding in the Brain
4.
Understanding the Importance of Red Cell Distribution Width (RDW) in Blood Tests
5.
Tumor Evolution Forecasting for Precision Oncology Decisions
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Newer Immunotherapies for Myeloma- A Comprehensive Overview
2.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
3.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II
4.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
5.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation